Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 17 |
| Active Pipeline (Recruiting Now) | 5 (2) |
| Completed vs Stopped Early | 5 / 3 (17.6%) |
| Median Closed Actual Enrollment | 32 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| The Royal Marsden NHS Foundation Trust | London | 5 |
| University College London Hospital | London | 3 |
| The Christie NHS Foundation Trust | Manchester | 3 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT04985266 | A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus | Phase II | RECRUITING |
| NCT04920708 | Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression | Phase II | ACTIVE NOT RECRUITING |
Explore interactive annual charts and M&A subsidiary rollups in the Royal Marsden NHS Foundation Trust Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.